Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C76H52O46.C16H19BrN2 |
| Molecular Weight | 2020.438 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C2=CC=CC=N2.OC3=CC(=CC(O)=C3O)C(=O)OC4=CC(=CC(O)=C4O)C(=O)OC[C@H]5O[C@@H](OC(=O)C6=CC(O)=C(O)C(OC(=O)C7=CC(O)=C(O)C(O)=C7)=C6)[C@H](OC(=O)C8=CC(O)=C(O)C(OC(=O)C9=CC(O)=C(O)C(O)=C9)=C8)[C@@H](OC(=O)C%10=CC(O)=C(O)C(OC(=O)C%11=CC(O)=C(O)C(O)=C%11)=C%10)[C@@H]5OC(=O)C%12=CC(O)=C(O)C(OC(=O)C%13=CC(O)=C(O)C(O)=C%13)=C%12
InChI
InChIKey=YZAQFXRNFPSDQX-RKGSNTPUSA-N
InChI=1S/C76H52O46.C16H19BrN2/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26;1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h1-20,52,63-65,76-101H,21H2;3-9,11,15H,10,12H2,1-2H3/t52-,63-,64+,65-,76+;15-/m10/s1
DEXBROMPHENIRAMINE is an alkylamine derivative with anticholinergic and sedative properties. It is a histamine H1-receptor antagonist that competes with histamine for the H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. The antagonistic action of this agent blocks the activities of endogenous histamine, which subsequently leads to temporary relief from the negative histamine-mediated symptoms of an allergic reaction such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of the gastrointestinal smooth muscle. DEXBROMPHENIRAMINE as a part of combination medicine is used to treat symptoms of the common cold or seasonal allergies, including sneezing, runny or stuffy nose, and itchy, watery eyes.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL231 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | PANATUSS PEDIATRIC DROPS DXP Approved UseUses:
- Temporarily relieves cough due to minor throat and bronchial irritations as may occur with the common cold;
- Temporarily relieves nasal congestions due to common cold;
- For temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or allergic rhinitis. Launch Date2005 |
|||
| Palliative | PANATUSS PEDIATRIC DROPS DXP Approved UseUses:
- Temporarily relieves cough due to minor throat and bronchial irritations as may occur with the common cold;
- Temporarily relieves nasal congestions due to common cold;
- For temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or allergic rhinitis. Launch Date2005 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27.98 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/ |
6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXBROMPHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
234.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/ |
6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXBROMPHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/ |
6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXBROMPHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.3 % 1 times / day steady, ophthalmic Recommended Dose: 0.3 %, 1 times / day Route: ophthalmic Route: steady Dose: 0.3 %, 1 times / day Sources: |
unhealthy, adult n = 1 Health Status: unhealthy Condition: Allergic conjunctivitis Age Group: adult Sex: unknown Population Size: 1 Sources: |
|
6 mg 4 times / day steady, oral Recommended Dose: 6 mg, 4 times / day Route: oral Route: steady Dose: 6 mg, 4 times / day Co-administed with:: pseudoephedrine sulfate(120 mg) Sources: |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine. | 2008 Dec |
|
| Possibilities of column coupling electrophoresis provided with a fiber-based diode array detection in enantioselective analysis of drugs in pharmaceutical and clinical samples. | 2008 Jan 25 |
|
| Acute cough: a diagnostic and therapeutic challenge. | 2009 Dec 16 |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
686390
Created by
admin on Fri Dec 15 21:31:27 GMT 2023 , Edited by admin on Fri Dec 15 21:31:27 GMT 2023
|
PRIMARY | RxNorm | ||
|
XI2Z928Y41
Created by
admin on Fri Dec 15 21:31:27 GMT 2023 , Edited by admin on Fri Dec 15 21:31:27 GMT 2023
|
PRIMARY | |||
|
139031032
Created by
admin on Fri Dec 15 21:31:27 GMT 2023 , Edited by admin on Fri Dec 15 21:31:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
